Patent Application
20230366889
This application is being filed with a sequence listing in electronic format. The sequence listing provided as a file titled, “55797_Seqlisting.txt,” created Sep. 20, 2021, and is 7,091 bytes in size. The information in the electronic format of the sequence listing is incorporated herein by reference in its entirety.
The functions served by protein post-translational modifications (PTMs) such as arginine methylation1, phosphorylation2, ubiquitination3, glycosylation4-5 and O-linked β-N-acetylglucosamine modification6-7 in the biology of the cell have now been well established. Proteins can also undergo spontaneous chemical degradation, readily detectable after aging or under stressed conditions9. The current literature contains many studies on the characterization of such chemical modifications identified in both cellular proteins and biotherapeutics10-12. Examples of such chemical modifications include methionine and tryptophan oxidation, asparagine deamidation, as well as aspartate isomerization13-16. Most stable modifications display a very specific mass change such as +15.994 Da for tryptophan (Trp) and methionine (Met) oxidation and +0.984 Da for asparagine (Asn) deamidation18. However, with aspartate isomerization, there is no change in mass after the modification.
During the development of biotherapeutics for human application, it is advantageous to identify chemical liabilities that negatively impact the activity and stability of the candidate molecules as early as possible. The proteins are typically subjected to a series of forced degradation studies to determine their stability, appropriate shelf life, suitable storage and transport conditions, a process known as “Molecular Assessment”30-31. The molecules that are affected by the chemical modifications may be deselected or be subjected to another round of protein engineering to mitigate the adverse effect32. Most chemical modifications can be identified by the liquid chromatography-tandem mass spectrometry (LC-MS/MS) and data processing33-35. Identification of aspartate isomerization presents a more challenging problem. Because of the resultant structural impact after the modification, isoAsp formation in several therapeutic mAb has been shown to result in loss of activity36-38. Its occurrence during biotherapeutics manufacturing must therefore be carefully monitored and controlled39.
Thus, there is a need in the art for efficient methods of detection of isoaspartic acid (isoAsp).
In one aspect, disclosed herein are methods of processing a protein. In various embodiments, the method comprises: (a) digesting a protein into peptides, (b) subjecting the peptides to mass spectrometry and measuring fragmentation, by mass spectrometry (such as tandem-mass spectrometry (MS/MS)), of a peptide bond N-terminal to an isoaspartic acid (isoAsp); (c) comparing the fragmentation to a threshold, wherein the fragmentation exceeding the threshold is indicative of the presence of the isoAsp in the peptide being analysed and ultimately in the protein. In some embodiments, the methods further comprise the (d) rejecting the protein comprising the isoAsp, or engineering the protein to remove the isoAsp.
In various embodiments, the methods described herein further comprises reducing the charge (z) of the peptides subject to mass spectrometry prior to (b). In some embodiments, the peptides subject to mass spectrometry in (b) are singly-charged. In any of the described methods, the fragmentation is measured as a b-series peak, a y-series peak, or both.
The disclosed methods may be carried out with any type of mass spectrometry methods. For example, the mass spectrometry for use in the methods described herein include matrix-assisted laser desorption/ionization time-of-flight/time-of-flight (MALDI-TOF/TOF) or liquid chromatography-mass spectrometry/mass-spectrometry (LC-MS/MS). In related embodiments, the LC-MS/MS comprises electrospray ionization.
In any of the disclosed methods, digesting a protein into peptides may be carried out after thermal stressing of the protein followed by enzymatic digestion with a proteolytic enzyme. For example, the proteolytic enzyme comprises at least one of chymotrypsin, trypsin, pepsin, papain, or elastase.
In various embodiments, the isoAsp is not adjacent to an asparagine in the amino acid sequence of the protein and/or is not adjacent to a threonine in the amino acid sequence of the protein.
In various embodiments, the isoAsp is adjacent to an adjacent aspartate residue in the amino acid sequence of the protein. In related embodiments, the adjacent aspartate is isoAsp or L-Asp.
In the disclosed methods, a threshold level of fragmentation of the peptide is used as a standard for determining whether isoAsp is present in the protein. For example, the threshold may be the level of fragmentation of the peptide bond of a control peptide, such as a synthetic peptide. In various embodiments, the fragmentation of the peptide exceeds the threshold when a b-peak and/or a y-peak of the fragmented peptide bond N-terminal to isoAsp is present.
In various embodiments, the methods described herein further comprise subjecting a control peptide to mass spectrometry, thereby obtaining the fragmentation of the peptide bond of the control peptide. In various embodiments, the control peptide is not subjected to thermal stressing. In related embodiments, the control peptide is a synthetic peptide. In various embodiments, the synthetic peptide may be used for comparison to one or more protein sample(s). In various embodiments, the threshold is the level of fragmentation of a peptide bond N-terminal to an L-Asp in a control peptide. In various embodiments, the fragmentation of the peptide bond of the control peptide is provided as an electronically-stored value or is provided from a reference peptide subjected to the same mass spectrometry methods as the protein sample being tested.
In any of the disclosed methods, the protein comprises or consists of an antibody, antibody protein product, bispecific T-cell engager (BiTE®) molecule, antibody fragment, antibody fusion peptide or antigen-binding fragment thereof, peptide, growth factor, or cytokine. In related embodiments, the antibody is a polyclonal or monoclonal antibody. As used herein, the term “antibody protein product” refers to any one of several antibody alternatives which in various instances is based on the architecture of an antibody but is not found in nature. In some aspects, the antibody protein product has a molecular-weight within the range of at least about 12 kDa-1 MDa, for example at least about 12 kDa-750 KDa, at least about 12 kDa-250 kDa, or at least about 12 kDa-150 kDa. In certain aspects, the antibody protein product has a valency (n) range from monomeric (n=1), to dimeric (n=2), to trimeric (n=3), to tetrameric (n=4), if not higher order valency. Antibody protein products in some aspects are those based on the full antibody structure and/or those that mimic antibody fragments which retain full antigen-binding capacity, e.g., scFvs, Fabs and VHH/VH (discussed below). The smallest antigen binding antibody fragment that retains its complete antigen binding site is the Fv fragment, which consists entirely of variable (V) regions. A soluble, flexible amino acid peptide linker is used to connect the V regions to a scFv (single chain fragment variable) fragment for stabilization of the molecule, or the constant (C) domains are added to the V regions to generate a Fab fragment [fragment, antigen-binding]. Both scFv and Fab fragments can be easily produced in host cells, e.g., prokaryotic host cells. Other antibody protein products include disulfide-bond stabilized scFv (ds-scFv), single chain Fab (scFab), as well as di- and multimeric antibody formats like dia-, tria- and tetra-bodies, or minibodies (miniAbs) that comprise different formats consisting of scFvs linked to oligomerization domains. The smallest fragments are VHH/VH of camelid heavy chain Abs as well as single domain Abs (sdAb). The building block that is most frequently used to create novel antibody formats is the single-chain variable (V)-domain antibody fragment (scFv), which comprises V domains from the heavy and light chain (VH and VL domain) linked by a peptide linker of ˜15 amino acid residues. A peptibody or peptide-Fc fusion is yet another antibody protein product. The structure of a peptibody consists of a biologically active peptide grafted onto an Fc domain. Peptibodies are well-described in the art. See, e.g., Shimamoto et al., mAbs 4(5): 586-591 (2012). Other antibody protein products include a single chain antibody (SCA); a diabody; a triabody; a tetrabody; bispecific or trispecific antibodies, and the like. Bispecific antibodies can be divided into five major classes: BsIgG, appended IgG, BsAb fragments, bispecific fusion proteins and BsAb conjugates. See, e.g., Spiess et al., Molecular Immunology 67(2) Part A: 97-106 (2015). In exemplary aspects, the antibody protein product comprises or consists of a bispecific T cell engager (BiTE®) molecule, which is an artificial bispecific monoclonal antibody. BiTE® molecules are fusion proteins comprising two scFvs of different antibodies. One binds to CD3 and the other binds to a target antigen. BiTE® molecules are known in the art. See, e.g., Huehls et al., Immuno Cell Biol 93(3): 290-296 (2015); Rossi et al., MAbs 6(2): 381-91 (2014); Ross et al., PLoS One 12(8): e0183390.
In various embodiments, the methods described herein further comprise determining the position of the isoAsp in the protein. In various embodiments, the isoAsp is detected during a protein discovery process or during a protein production process. In various embodiments, absence of the isoAsp indicates suitability of the protein for further processing.
In various embodiments, the method further comprises rejecting the protein when the protein comprises isoAsp. “Rejecting” the protein includes, but is not limited to, halting or revising the protein production or purification process or disposing of the protein supply. If the protein production process is halted, additional processing may be carried out to further assess protein stability, molecular assessment, and/or quality control. In various embodiments, rejecting the protein comprises discarding or disposing of a quantity of product comprising the protein, and/or rejecting a clone that produces the protein.
In various embodiments wherein the method determines the protein comprises isoAsp, the method further comprises engineering the protein to remove the site that is susceptible to isoAsp formation. For example, the engineering comprises inducing a point mutation at the position of the isoAsp in the protein.
In various embodiments, the presence of isoAsp results in structural changes in the peptide backbone compared to a reference protein comprising an L-Asp at the same position.
In various embodiments, the presence of isoAsp inhibits potency of the protein. In various embodiments, the presence of isoAsp increases the immunogenicity of the protein compared to a reference protein comprising an L-Asp at the same position. In addition, the disclosure provides for methods of evaluating the potency and/or immunogenicity of a protein by determining whether the protein comprises isoAsp.
In any of the described methods, at least one of the peptides comprises a positive charge at the N terminus of the peptide.
In various embodiments and prior to subjecting the peptide to mass spectrometry analysis, the method further comprises introducing a positive charge to the N terminus of the peptide. In various embodiments, the positive charge is introduced by incubating the peptide with an N-terminal charge-derivatizing reagent. In certain embodiments, the N-terminal charge-derivatizing reagent is (N-succinimidyloxycarbonylmethyl) tris (2,4,6 trimethoxyphenyl) phosphonium bromide (TMPP) or a derivative thereof. In certain embodiments, the N-terminal charge-derivatizing reagent is tris[2,4,6-trimethoxyphenyl]phosphonium acetyl (TMPP-Ac) or a derivative thereof. In various embodiments, the isoAsp is within 5 amino acid residues of a C-terminus of at least one of the peptides, for example within 4, 3, 2, or 1 amino acid residues of the C-terminus.
In another aspect, disclosed herein is a mass spectrometry system configured for performing the methods described herein. In various embodiments, the fragmentation of a peptide bond N-terminal to the isoAsp is measured using the mass spectrometry system disclosed herein. In related embodiments, the fragmentation exceeding the threshold is indicative of the presence of isoAsp in a protein. In addition, the disclosure provides for methods of determining the presence of isoAsp in a protein using a mass spectrometry system of the disclosure.
In various embodiments, the mass spectrometry performed is matrix-assisted laser desorption/ionization time-of-flight/time-of-flight (MALDI-TOF/TOF). In various embodiments, the mass spectrometry performed is liquid chromatography-mass spectrometry/mass-spectrometry (LC-MS/MS), such as electrospray ionization LC-MS/MS.
The use of the singular includes the plural unless specifically stated otherwise. The use of “or” means “and/or” unless stated otherwise. The use of the term “including”, as well as other forms, such as “includes” and “included,” is not limiting.
“About” or “approximately” means, when modifying a quantity (e.g., “about” 3:1 ratio), that variation around the modified quantity can occur. These variations can occur by a variety of means, such as typical measuring and handling procedures, inadvertent errors, ingredient purity, and the like.
“Comprising” and “comprises” are intended to mean that methods include the listed elements but do not exclude other unlisted elements. The terms “consisting essentially of” and “consists essentially of,” when used in the disclosed methods include the listed elements, exclude unlisted elements that alter the basic nature of the method, but do not exclude other unlisted elements. Embodiments defined by each of these transition terms are within the scope of this disclosure.
Disclosed herein are methods of processing a protein. In exemplary aspects, the protein is a large peptide/polypeptide (>50 amino acids), antibody, antibody protein product, bi-specific T cell engager (BiTE®) molecule, antibody fragment, antibody fusion peptide or antigen-binding fragments thereof. In exemplary embodiments, the method comprises using mass spectrometry to detect isoAsp in a protein. The disclosed methods are advantageous, because, in contrast to conventional detection of isoAsp, neither specialized instrumentation nor ion chemistry is required. The present disclosure also provides mass spectrometry systems configured for performing the methods disclosed herein. In some embodiments, the protein has at least two consecutive aspartate residues in its amino acid sequence.
In exemplary embodiments, the method comprises: (a) digesting a protein into peptides, (b) subjecting the peptides to mass spectrometry and measuring fragmentation, by mass spectrometry (such as tandem-mass spectrometry), of a peptide bond N-terminal to an isoAsp; (c) comparing the fragmentation to a threshold, wherein the fragmentation exceeding the threshold is indicative of the presence of the isoAsp in the protein; and (d) rejecting the protein comprising the isoAsp, or engineering the protein to remove the isoAsp. As used herein, isoAsp, unless stated otherwise, refers to an isoAsp residue in the context of a protein or peptide. Further description of the method is provided below. It is contemplated that small amounts of isoAsp may be tolerated for some applications. Accordingly, in some embodiments, (d) comprises rejecting the protein if the isoAsp is at or above a specified level. In some embodiments, the method further comprises introducing a positive charge to the N terminus of the peptides using an N-terminal charge-derivatizing reagent, such as TMPP, prior to subjecting the peptide to mass spectrometry.
The experiments provided herein demonstrate that the peptide bond N-terminal to an isoAsp residue within the amino acid sequence of a peptide or protein was more susceptible to MALDI-TOF/TOF fragmentation. This finding was employed to distinguish an isoAsp containing peptide from its unmodified counterpart. In various embodiments, the method comprises measuring, by mass spectrometry, the fragmentation of a peptide bond N-terminal to an isoAsp residue. Mass spectrometry is used to measure the mass/charge of ions. In some embodiments, the charge is associated with the C-terminal region of the peptide and is known as the “y-series peak” or “y-peak”. In some embodiments, the charge is associated with the N-terminal region of the peptide and is known as the “b-series peak” or “b-peak”. In some embodiments, the fragmentation is measured as a b-series peak, a y-series peak, or both.
In various embodiments, to determine the presence of isoAsp in a protein sample, the fragmentation of a protein sample is compared to a threshold, where the fragmentation exceeding the threshold is indicative of the presence of the isoAsp in the protein. The threshold may be determined by measuring fragmentation of a control peptide or the threshold may be a reference value that is known to correspond with fragmentation of unmodified proteins, such as protein that does not comprise isoAsp. In some embodiments, the threshold may be based on presence of a b-peak and/or a y-peak of the fragmented peptide bond N-terminal to isoAsp. In related embodiments, the fragmentation exceeds the threshold when a b-peak and/or a y-peak of the fragmented peptide bond N-terminal to isoAsp is present in the protein sample.
In some embodiments, the fragmentation of a protein sample is compared to the fragmentation to that of a control peptide. The control peptide is also referred to as a “reference peptide.” The control or reference peptide may be a peptide or protein which does not contain an isoAsp residue or has been engineered to remove isoAsp and/or contain an L-Asp residue. In related embodiments, the threshold may be based on the level of fragmentation of a peptide bond N-terminal to an L-Asp in a control peptide. The threshold refers to a level of fragmentation that is indicative of the presence of at least one isoAsp in a protein or peptide.
In some embodiments, the control peptide is optionally subjected to the same method (including (a), (b) and/or (c)) as the protein sample. In some embodiments, the fragmentation of the peptide bond of the control peptide is provided as an electronically-stored value or a reference value. An exemplary reference value is based on mass spec data from previously processed proteins that is stored electronically. In some instances, processing software generate electronic rules on isoAsp fragmentation and intensity of fragment ions N-terminal to the isoAsp when compared to a control peptide. The control peptide may be a synthetic peptide particularly designed based on the protein being processed. Alternatively, the control peptide may be a fragment of a protein that does not comprise isoAsp and preferably does not comprise any modified or altered amino acids. In particular, the control protein comprises an L-Asp at the same position as the protein in the sample.
It was also demonstrated that higher energy collisional dissociation (HCD) by electrospray LC-MS/MS of only the singly charged ion of an isoAsp containing peptide produced similar tandem mass spectrometry (MS/MS) fragmentation to that generated by MALDI-TOF/TOF.
In various embodiments, the disclosed methods comprise digesting a protein sample to be tested, into peptides. The digestion may be carried out using any known methods that would digest a protein into peptides. For example, digestion of the sample protein may be carried out using enzymatic digestion using a proteolytic enzyme after thermal stressing has been performed.
Thermal degradation refers to deterioration of polymeric molecules as a result of exposing proteins and/or peptides to increased temperatures, and in some instances excessively high temperatures. In various embodiments, thermal degradation is carried out at 38-400° C. In exemplary embodiments, thermal degradation is carried out at 40° C. for 2-4 weeks, 3-6 months at 40° C., 1-2 months at 25° C., 1 month at 25° C., 3-6 months at 4° C. or 6 months at 4° C. In various embodiments, thermal degradation is carried out at 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 55, 60, or 65° C. In various embodiments, thermal degradation is carried out for 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours or 1 day, 2 days, 3, days, 4 days, 5 days, 6 days, 7 days or 1 week, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days or at least 2 weeks; at least 3 weeks, at least 4 weeks or at least 1 months, at least 5 weeks, at least 6 weeks, at least 8 weeks or at least 2 months, at least 3 months, at least 4 months, at least 5 months, or at least 6 months. In various embodiments, the thermal degradation is carried out between pH 5-8. In exemplary embodiments, thermal degradation is carried out at pH 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, or pH 8.0. In various embodiments, the thermal degradation is performed accordingly to the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines. In some embodiments, thermal degradation comprises incubation at 40° C. for 2-4 weeks (such as 2 weeks) at a pH in a range of pH 5 to pH 8.
Enzymatic digestion of proteins involves cleaving the peptide bond with an enzyme to form peptides. The digestion may be carried out with enzymes having varying degrees of specificity. For example, enzymatic digestion may be carried out with one or more proteolytic enzymes. Proteolytic enzymes include, but are not limited to, chymotrypsin, trypsin, pepsin, papain, or elastase. In some embodiments, the protein sample may be reduced and alkylated prior to digestion with a proteolytic enzyme and subsequently analyzed by mass spectrometry. The protein may be reduced with redox agents such as dithiothreitol (DTT), β-mercaptoethanol and TCEP (Tris (2-carboxyethyl) phosphine). The protein may be alkylated with a sulfhydryl reagent such as iodoacetamide (IAM), iodoacetic acid (IAA) or another electrophile to prevent reformation of disulfide linkages. In various embodiments, both the protein sample and control sample (control peptide) are digested with a proteolytic enzyme. In various embodiments, the protein sample is thermally degraded and subsequently analyzed by mass spectrometry.
Chemical Modification of Isoaspartate Containing Peptides with a N-Terminal Charge-Derivatizing Reagent
It is observed herein that introducing a positive charge to the N terminus of the peptide(s) prior to mass spectrometry can enhance the intensity of the peak that identifies fragmentation N-terminal of isoAsp, such as the bn−1+H2O peak (where n is the residue number of the isoAsp in the peptide) compared to a reference peptide in which the positive charge is not introduced to the N-terminus (See Example 7). In various embodiments, the methods disclosed herein may further comprise N-terminal modification of peptides. In various embodiments, the method further comprises introducing a positive charge to the N terminus of the peptides, prior to mass spectrometry analysis. In various embodiments, the positive charge is introduced by incubating the peptides with an N-terminal charge-derivatizing reagent. An “N-terminal charge-derivatizing reagent” refers to reagents which have the ability add a positive charge to the N terminus of one or more peptides or proteins (i.e. agent which introduce a positively charged group, such as quaternary or tertiary ammonium and quaternary phosphonium groups at the N-terminus of a peptide or protein). Exemplary N-terminal charge-derivatizing reagents which may be used with methods disclosed herein include, but are not limited to, (N-succinimidyloxycarbonylmethyl) tris (2,4,6 trimethoxyphenyl) phosphonium bromide (TMPP), tris[2,4,6-trimethoxyphenyl]phosphonium acetyl (TMPP-Ac), 4-amidinobenzoic acid, nicotinic acid, 2-(6-amidinonaphthalen-2-yloxy)acetic acid, 4-(guanidinomethyl)benzoic acid, or derivatives thereof.
An exemplary structure of TMPP is shown in
In various embodiments, the introduction of a positive charge to the N terminus of one or more peptides, for example with a N-terminal charge-derivatizing reagent such as TMPP, may improve the detection of isoaspartate containing peptides by mass spectrometry. In various embodiments, an N-terminal charge-derivatizing reagent may be used when the isoAsp is within 5 amino acid residues of a C-terminus of at least one of the peptides. For example, the isoAsp may be within 4, 3, 2, or 1 amino acid residues of the C-terminus.
In certain embodiments the mass spectrometry method is MALDI-TOF/TOF. In exemplary embodiments, N-terminal modification of the peptide using a N-terminal charge-derivatizing reagent such as TMPP, followed by MALDI-TOF/TOF fragmentation, results in the detection of a more intense bn−1+H2O product ion in the modified peptide when compared to the aspartate counterpart (n denotes the residue number of the isoaspartate in the peptide).
In exemplary aspects, the method comprises using mass spectrometry to detect isoAsp in a sample. Mass spectrometry is used to measure the mass/charge of ions. In various embodiments, the mass spectrometry comprises or consists of matrix-assisted laser desorption/ionization time-of-flight/time-of-flight (MALDI-TOF/TOF). In various embodiments, the mass spectrometry comprises or consists of liquid chromatography-mass spectrometry/mass-spectrometry (LC-MS/MS), also referred to as liquid chromatography-tandem mass spectrometry.
Disclosed herein is the use of mass spectrometry to detect and determine the position of isoAsp residues in peptides. The experiments described herein demonstrate that the peptide bond N-terminal to the modified isoAsp residue was more susceptible to MALDI-TOF/TOF fragmentation. In the present disclosure, the two terms MALDI-TOF/TOF and MALDI-LIFT-TOF/TOF are used interchangeably. In exemplary embodiments, MALDI-TOF/TOF mass spectrometry is used to characterize and determine the position of isoAsp residues in synthetic peptides and proteolytically generated peptides from a protein sample. In alternative embodiments, LC-MS/MS mass spectrometry may be used. Without being limited by theory, it is contemplated that MALDI-TOF can be used in methods described herein with charge reduction. For methods comprising LC-MS/MS, the mass spectrometry may be preceded by charge reduction.
In various embodiments, the methods described herein further comprise charge reduction of the peptide sample prior to (b). Charge reduction (Smith. J Am Soc Mass Spectrom 2008, 19(5), 629-31, which is incorporated by reference in its entirety) is used to reduce peptide charge states to z=1+ for detection of isoAsp in a protein sample by mass spectrometry. In some embodiments, the peptides subject to mass spectrometry in (b) are singly-charged. The term “singly-charged” refers to peptide with +1 or −1 charge state. In some embodiments, the fragmentation is measured as a b-series peak, a y-series peak, or both.
In various embodiments, “charge reduction” as used herein, refers to decreasing the magnitude of the charge of the peptide, so as to decrease the number of charged species in the peptide, which may make the charge state of the peptide neutral (or closer to neutral). In some embodiments, the charge of peptide is reduced by making it smaller (e.g. by enzymatic digestion). In some embodiments, the charge of peptide is reduced by a favorable addition (e.g. the use of a basic chemical). In exemplary embodiments, charge reduction can be performed in the following ways. Firstly, the length of the peptide is reduced by using an enzyme other than trypsin, such as chymotrypsin. The resulting peptide would be smaller and therefore possess less charge. In this case, the charge state would by z=1+, therefore now amenable to LC-MS/MS HCD fragmentation. Secondly, the use of a basic chemical such as 1,8 diazabicyclo[5.4.0]-undec-7-ene (DBU) for example, to induced gas-phase base mediated charge stripping, therefore reducing the charge of the peptide from z=3+ to z=1+, for example, allowing for LC-MS/MS HCD fragmentation of the z=1+ ion.
The present disclosure also provides mass spectrometry systems configured for performing the methods disclosed herein. In various embodiments, the fragmentation of a peptide bond N-terminal to the isoAsp is measured using the mass spectrometry system disclosed herein. In related embodiments, the fragmentation of a peptide bond N-terminal to the isoAsp exceeding the threshold is indicative of the presence of isoAsp in a protein. In various embodiments, the mass spectrometry system is MALDI-TOF/TOF. In various embodiments, the mass spectrometry system is LC-MS/MS. In various embodiments, the mass spectrometry system uses higher energy collisional dissociation (HCD).
The protein sample (which, for conciseness, may also be referred to herein simply as a “protein”) comprises any type of protein that may be processed or analyzed for stability and/or structural integrity. In various embodiments, the protein sample so subjected to the methods disclosed herein, comprises or consists of a large peptide, antibody, antibody fragment, antibody fusion peptide or antigen-binding fragments thereof. In related embodiments, the antibody is a polyclonal or monoclonal antibody.
Aspartic acid (Asp) to isoaspartic acid (isoAsp) isomerization in therapeutic monoclonal antibodies (mAbs) and other biotherapeutics is a critical quality attribute (CQA) which requires careful control and monitoring during the discovery and production processes. The unwanted formation of isoAsp within biotherapeutics and resultant structural changes in the peptide backbone may negatively impact the molecule activity or become immunogenic, especially if the isomerization occurs within the complementarity determining region (CDR).
The methods disclosed herein may be used to monitor isoAsp during the protein discovery (Research) process or a protein production (Process Development) process. In various embodiments, an absence of the isoAsp indicates suitability of the protein for further processing. In various embodiments, the presence of isoAsp may result in one or more of the following changes to the protein: structural changes in the peptide backbone, change the protein activity, or increase the immunogenicity. In various embodiments, the presence of isoAsp results in structural changes in the peptide backbone compared to a reference protein comprising an L-Asp at the same position. In some embodiments, the presence of isoAsp inhibits potency of the protein. In various embodiments, the presence of isoAsp increases the immunogenicity of the protein compared to a reference protein comprising an L-Asp at the same position. As described herein, protein (e.g., a sample, clone, lot, or batch comprising the protein) may be rejected if the protein contains excessive amount of isoAsp (typically about 5% in the Research Discovery stage)
In various embodiments, rejecting the protein comprising the isoAsp comprises rejecting a quantity of product comprising the protein, or rejecting a clone that produces the protein. In various embodiments, the method further comprises reducing or inhibiting isoAsp by protein engineering. In various embodiments, the method further comprises engineering the protein to remove the site that is susceptible to aspartate isomerization comprises inducing a point mutation at the position of a nucleic acid encoding the isoAsp in the protein. In some embodiments, the protein comprising the isoAsp is rejected if the isoAsp is at or above a specified level.
Aspartic Acid (Asp) to Isoaspartic Acid (isoAsp) Isomerization
Aspartic acid (Asp) to isoaspartic acid (isoAsp) isomerization in therapeutic monoclonal antibodies (mAbs) and other biotherapeutics is a critical quality attribute (CQA) which requires careful control and monitoring during the discovery and production processes. The unwanted formation of isoAsp within biotherapeutics and resultant structural changes in the peptide backbone may negatively impact the molecule activity or become immunogenic, especially if the isomerization occurs within the complementarity determining region (CDR).
Characterization of isoaspartate (isoAsp) formation in a protein by canonical mass spectrometry (MS) can be a formidable task because the modified residue is isomeric with its unmodified counterpart19. The chemistry of isoAsp formation has been well documented (
Because of the additional methylene group introduced into the polypeptide backbone and the concomitant shortening and reorientation of the carboxyl side chain26, this structural change may impact the protein's function, becoming immunogenic27 or leading to unwanted aggregation and resulting in insolubility26. Isomerization of Asp1 and Asp7 in p-amyloid (As 1-42) was first identified in Alzheimer's Disease (AD) brain tissue and has been implicated to be responsible for initiating the pathological effect during the development of the disease28. In a recent study, Julian and associates29 demonstrated Aβ with isoAsp7 modification was resistant to proteolysis by the cathepsins commonly found in lysosomes. The authors also proposed an association between this lysosomal storage malfunction and the development of AD.
IsoAsp can be identified by automated Edman degradation where the Edman chemistry would terminate at the modified residue40. However, N-terminal sequencing is time consuming, requiring a larger amount of material when compared to LC-MS/MS. Lehmann41 reported the use of LC-MS/MS to analyze isoAsp in peptides and demonstrated that complementary b/y ion intensity ratios obtained by fragmentation of the (Asp/isoAsp)-X bond could be employed to distinguish between the modified residue from its unmodified counterpart. However, the MS/MS data presented by Bondarenko and co-workers42 suggested the observation made by Lehmann, may not be applicable to all isoAsp containing peptides. Identification of isoAsp in peptides by MALDI-Post Source Decay (PSD) has been reported by Fujii43 and Reilly44. By this technique, the former confirmed the detection of the isoAsp diagnostic ion yL-n+1-46 (where L represents the length of peptide (integer; total residue number), n is the position of the isomerized residue) first reported by Gonzalez45. Unfortunately, this ion is usually of very low intensity and is generally limited to peptides obtained by tryptic digestion. This group also evaluated the ratio yL−n:yL−n+1 from the PSD fragmentation of a series of tryptic-like synthetic peptides based on the sequence of crystallin. In general, for the isoAsp containing peptide, the intensity of the yL−n+1 is increased compared to a corresponding peptide containing L-Asp. The authors attributed this observation to the shorter isoaspartyl side chain interacting with the carbonyl group in the peptide bond N-terminal to the modified residue. Fuji et al. utilized Post source decay-matrix assisted laser desorption ionization (MALDI-PSD) to evaluate the amount of isoAsp formation from a tryptic digest of human aged lens crystallin; a relatively small protein. In contrast, the methods disclosed herein are able to detect isoAsp in larger peptides and proteins with consecutive aspartate residues.
Detection of isoAsp diagnostic ions using either ECD or ETD (c′+57 and z·57) has been reported16,46-48. In contrast, the instant disclosure describes fragmentation of the singly charged ion that allows isoAsp modification to be distinguished from its unmodified counterpart (Asp). Depending on the peptide sequence, the signature ions can be of low intensity, thus making interpretation challenging. IsoAsp containing peptides derived from β-2 microglobulin have also been evaluated by Costello49 using MALDI-ISD (in-source decay). In the presence of hydrogen donating matrix, the ECD-like c′+57 and z·-57 diagnostic ions were also observed. The use of radical directed dissociation (RDD) in identifying amino acid isomers was described by Julian. The RDD method has been successfully demonstrated in identifying isoAsp formation and epimerization of serine and other amino acids50-51. Smith52 reported separation of four synthetic derivatives of β-amyloid peptides (residues 6-16) with Asp7 being unmodified, replaced with D-Asp, L-isoAsp or D-isoAsp using SLIM (structures for lossless ion manipulations) instrumentation. Studies by Cooks53 demonstrated the use of ion chemistry to distinguish Asp and isoAsp containing peptides. The carboxylate side chain was modified with carbodiimide to obtain acylisourea. Subsequent 1,3-acyl shift led to the formation of N-acylurea. Under collision induced dissociation (CID) conditions, distinct fragments of acylisourea and N-acylurea can be detected. However, because of steric hindrance imposed by the isoAsp side chain, formation of N-acylurea is not favored. Thus, the predominant fragment observed with the modified peptide was that derived from acylisourea. In addition, Popov54-55 reported using MALDI-TOF/TOF with CID to explore fragmentation of Aβ (residues 1-42) containing isoAsp7. By using a series of synthetic peptide standards, these investigators developed a label-free quantitation method of Aβ. However, these investigators do not appear to mention identification of isoAsp or mass spectra for identifying isoAsp itself. Moreover, it is not expected that the methods reported by these investigators would have detected consecutive isoAsp in peptides with consecutive aspartate residues.
In various embodiments, the methods disclosed herein may be used to determine the position of isoAsp residues in a protein. In addition, the disclosed herein may be used for quality control during the protein production process. The disclosed method may also be used to assess stability or structural stability of the protein after storage or exposure to temperature changes, light or other environmental or chemical factors.
The following examples are given merely to illustrate the present invention and not in any way to limit its scope.
Nine pairs of synthetic peptides, comprising either Asp or isoAsp, were obtained from Anaspec (Freemont, CA) or synthesized in-house. The peptide sequences are: LD/isoDA, GD/isoDLLLK, GLD/isoDLLK, ALD/isoDGK, ALD/isoDEK, ALD/isoDGE, AD/isoDLGK, GFYPSDIAVEWESD/isoDGQPENNYK and VVSLTVLHQD/isoDWLNGK. The delta-sleep inducing peptides DSIP and p-Asp DSIP (WAGGDASGE (SEQ ID NO: 2) and WAGGisoDASGE (SEQ ID NO: 1) were purchased from Bachem (Torrance, CA). The MS grade proteolytic enzymes chymotrypsin and trypsin were purchased from Thermos Scientific (Waltham, MA). Dithiothreitol (DTT) and iodoacetamide (IAM) were obtained from Sigma Aldrich (St Louis, MO). The MALDI matrix used (4-HCCA) was from Bruker Daltonics (Billerica, MA). All other reagents used were of the highest grade commercially available. Optima LC-MS grade solvents were used throughout.
The therapeutic mAb, at a concentration of 1.26 mg/mL was incubated in 0.1 M ammonium bicarbonate (pH 7.8) at 40° C. for 2 weeks to induce aspartate isomerization. The sample was reduced (DTT) and alkylated (IAM) prior to digestion with trypsin or chymotrypsin and subsequent LC-MS/MS analysis.
MALDI-MS was performed by using a Bruker UltrafleXtremeTOF/TOF mass spectrometer, equipped with a 2,000 Hz smartbeam II (Nd:YAG) laser. 4-HCCA was used as the matrix (saturated solution in 0.1% TFA/50% acetonitrile).
The column used was an Acquity UPLC peptide BEH C18 (2.1×150 mm, 1.7 μm) column. Solvent A was 0.1% formic acid in water and solvent B was 0.1% formic acid in acetonitrile. The column was equilibrated in 1% B at a flow rate of 0.25 mL/min and at 50° C. Upon sample application, the column was washed with 1% B for 8 min before a linear gradient from 1 to 55% B over 70 min was applied. Peptide elution was monitored by absorbance at 214 nm and the eluted peptides were introduced into a Q-Exactive for MS and MS/MS. A spray voltage of 3.5 kV was used. The data-dependent MS method consisted of a full MS from m/z 300-2000 at a resolution of 70,000. This was followed by HCD (at resolution 17,500) of the 10 most abundant precursors. AGC target values were set at 1 E6 for full MS and 5e4 for HCD. An isolation width of 2 Da and a NCE of 27 were employed. The tandem MS data obtained was analyzed by for peptide identification.
Within the current literature, the major application of MALDI-MS has shifted towards imaging56-57, identification of bacterial species58 and high throughput screening of small molecules library59-61. The LIFT-TOF/TOF technology introduced almost two decades ago has demonstrated its successful application in peptide characterization62. Briefly, as opposed to the slow heating process as a function of the low energy ion-neutral collision that is CID63, the LIFT technology is based on the result of metastable ion fragmentation in the field-free region of the MS, followed by precursor and fragment ion gating prior to energy focusing in a reflectron64.
A similar observation was made by Indeykina68 in their tandem-MS study on a binary mixture of synthetic amyloid-3 (residues 1-16) peptides containing either Asp7 or isoAsp7. It is likely that the isoAsp containing peptide is more easily ionized. In addition, upon ESI infusion of the 2 peptides WAGG isoD/D ASGE (
To put the above observations into the context of a real-life therapeutically relevant mAb, the MALDI-TOF/TOF method was used to identify an isomerized Asp residue in a mAb after thermally induced forced degradation. It has been well documented that a commercial mAb has an Asp residue at position 102 in the CDR3 domain of its heavy chain that has the propensity to undergo isomerization and modification of which results in loss of activity37, 69.
In this example, the mAb was incubated in pH 7.8 and at 40° C. for 2 weeks followed by reduction, alkylation and tryptic digestion. An unstressed mAb treated under identical conditions was used as control. Upon thermal stressing, other modifications such as Asn deamidation and Met oxidation were also present. Because they have been previously identified and documented by others70, Asn deamination and Met oxidation were not examined in these sets of experiments. Therefore, this disclosure describes characterization of heavy chain CDR3 Asp102 isomerization.
Because the tryptic peptide was large (26 residues) an experiment was therefore carried out to evaluate if a shorter peptide would have an improved MALDI-TOF/TOF spectrum. Both the thermal stressed and control commercial mAb were digested with chymotrypsin after reduction and alkylation and the peptides were identified by LC-MS/MS. The decapeptide C96 SRWGGDGFY104 (SEQ ID NO: 4) again was found to resolve into two chromatographically separated peaks with identical m/z=602.73 ([M+2H]2+;
Initially, it was unclear how only the MALDI-TOF/TOF was successful in identifying isoAsp containing peptide but not LC-MS/MS. During identification of the chymotryptic peptides by LC-MS/MS, HCD analysis of the singly charged C96-Y104 was observed to produce a highly comparable spectrum to the MALDI TOF/TOF data, that is, a predominant b6+H2O ion, indicative of Asp102 being the isomerized residue (
The antibody, at 1.26 mg/mL was incubated in 0.1 M ammonium bicarbonate (pH 7.8) at 40° C. for 2 weeks prior to being frozen at −70° C. for further experiments. In a typical digestion, 100 μL of the incubated antibody was dried by vacuum centrifugation. The sample was dissolved in 50 μL of 8 M urea in 0.1 M Tris at pH 7.5 before being reduced with 10 mM DTT at 50° C. for 1 hr and followed by alkylation with 20 mM iodoacetamide in the dark for 30 min at room temperature. Alkylation was quenched by the addition of DTT. The sample was diluted with 150 μL of 0.1 M Tris at pH 7.5 and either digested with 1% by weight of trypsin or chymotrypsin. Another aliquot of the antibody that has not been subjected to thermal stressing was treated in an identical fashion served as the control. Another set of heat stressed experiments was performed by incubating the antibody in pH 5.2. The amount of heavy chain Asp102 isomerization was similar and only the data at pH 7.8 was provided here.
MALDI-MS was performed by using a Bruker UltrafleXtremeTOF/TOF mass spectrometer, equipped with a 2,000 Hz smartbeam II (Nd:YAG) laser. 4-HCCA was used as matrix (10 mg/mL in 0.1% TFA/50% acetonitrile). 1 μL of peptide was mixed with an equi-volume of matrix before 1 μL of the mixture was spotted on an MTP 384 ground steel target plate, air-dried and inserted into the instrument for mass measurement. The mass spectrometer was set in the positive mode using a 21 kV acceleration voltage and a 25 kV reflectron voltage. The laser power was optimized and in a typical experiment, 5,000 laser shots were accumulated to create the spectra. Fragmentation of selected peptides was recorded using the LIFT cell technology. An initial acceleration voltage of 7.5 kV and a LIFT cell acceleration voltage of 19 kV were employed. Laser power for both the precursors and the fragments were optimized. Usually, about 8,000 to 10,000 laser shots were used in recording the fragmentation data.
The MALDI-TOF/TOF data of 8 pairs of synthetic peptides are further illustrated in
In summary, the data provided herein demonstrates that fragmentation using MALDI-TOF/TOF provides a simple and robust, label-free analytical method to identify the location of the isoAsp residue. This was demonstrated in peptide standards and a thermally degraded therapeutically relevant mAb. The peptide bond N-terminal to the isoAsp residue was demonstrated to be more labile to fragmentation by PSD. LC-MS/MS HCD fragmentation of a singly charged (z=1+) isoAsp containing peptide produces MS/MS fragmentation data highly comparable to MALDI-TOF/TOF fragmentation data. Additionally, the potential for online LC-identification has been discussed herein, by the implementation of charge reduction followed by LC-MS/MS (HCD), but again, relying on chromatographic separation for unequivocal identification. Online LC-MS/MS identification, as used herein, refers to utilizing electrospray ionization and online chromatographic separation of digested peptides followed by MS and MS/MS detection and fragmentation respectively. The method disclosed herein is improved using online LC-MS/MS identification because the manual collecting step can be skipped. Collecting the chromatographically separated peptides of interest manually is time-consuming. Both targeted LC-MS/MS fragmentation of the z=1+ ion and charge reduction could have important implication if applied to late stage Process developments analytical methods, such as the Multi Attribute Method74.
A potential limitation of this MALDI-TOF/TOF method is that the Asp and isoAsp containing peptide must display chromatographic separation, therefore allowing collection and subsequent MALDI-TOF/TOF analysis. However, if chromatographic separation can be achieved, isoAsp determination is straight forward and unequivocal.
The following example describes experiments performed to detect isoAsp in a sample of heat stressed antibody protein product comprising adjacent isoaspartic acid and L-aspartic acid.
A sample of thermal stressed antibody protein product (3 weeks at 40° C.) was reduced, alkylated with iodoacetamide and digested with trypsin as described above in Example 4. The digest was subsequently analyzed by LC-MS/MS (Tryptic mapping Filename: QE20200623-01). Analysis of the spectrum revealed two main peaks and a small shoulder (
The Orbitrap Fusion was used to specifically fragment the 1+ species of the peptide and to adapt EThcD as a routine method for isoAsp identification.
Evaluation of 2 synthetic peptides with the modified residue proximal to the C-terminus (GFYPSDIAVEWESNGQPENisoDYK (SEQ ID NO: 27) & GFYPSDIAVEWESNGQPEisoDNYK (SEQ ID NO: 25)) by the MALDI-TOF/TOF method described in Example 1 shows that while there is an increase in fragmentation of the peptide bond N-terminal to the modified residue, the enhancement was of smaller magnitude, thus making data interpretation more challenging (
All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.
The use of the terms “a” and “an” and “the” and similar referents in the context of describing the disclosure (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The terms “comprising,” “having,” “including,” and “containing” are to be construed as open-ended terms (i.e., meaning “including, but not limited to,”) unless otherwise noted.
Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range and each endpoint, unless otherwise indicated herein, and each separate value and endpoint is incorporated into the specification as if it were individually recited herein.
All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is intended merely to better illuminate the disclosure and does not pose a limitation on the scope of the disclosure unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the disclosure.
Preferred embodiments of this disclosure are described herein, including the best mode known to the inventors for carrying out the disclosure. Variations of those preferred embodiments can become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventors expect skilled artisans to use such variations as appropriate, and the inventors intend for the disclosure to be practiced otherwise than as specifically described herein. Accordingly, this disclosure includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the disclosure unless otherwise indicated herein or otherwise clearly contradicted by context.
This application claims priority to U.S. Provisional Patent Application No. 63/086,557, filed Oct. 1, 2020 and U.S. Provisional Patent Application No. 63/218,186, filed Jul. 2, 2021, which are hereby incorporated by reference in their entirety.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US21/52783 | 9/30/2021 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 63218186 | Jul 2021 | US | |
| 63086557 | Oct 2020 | US |
